Advertisement

Topics

Astellas Pharma GmbH Company Profile

07:37 EDT 22nd June 2018 | BioPortfolio

Aktuelle Studie belegt: Fluvastatin senkt die Blutfette sicher und effektiv unabhängig von der Tageszeit Dresden, 6. Oktober 2005. Die Retard-Formulierung von Fluvastatin wirkt effektiv und sicher, auch unabhängig vom Zeitpunkt der Einnahme. Das Präparat ermöglicht eine optimale Blutfetteinstellung über 24 Stunden, ganz gleich, zu welchem Zeitpunkt des Tages - morgens oder abends - das Medikament eingenommen wird. Dies fördert die Compliance, da der Zeitpunkt der Tabletteneinnahme individuell an den jeweiligen Patienten angepasst werden kann. Ein Vorteil für den Arzt und den Patienten. Zu diesem Ergebnis kommt eine neue Studie des Klinischen Instituts für Medizinische und Chemische Labordiagnostik der Universität Graz, die erstmals am 6. Oktober auf der Herbsttagung der Kardiologen in Dresden präsentiert wurde

Location

Postfach 80 06 28
Munich
München
D-81606
Germany

Contact

Phone: (089) 45 44 - 01
Fax: (089) 45 44 - 13 29
Email: info@de.astellas.com


News Articles [1089 Associated News Articles listed on BioPortfolio]

Astellas Makes Leadership Changes in Canada and U.S.

Sabus appointed GM of Astellas Pharma Canada; Gerber and O'Keefe promoted to new roles in U.S. sales organization Steve Sabus has been named general manager of Astellas Pharma Canada , effective A...

Astellas Pharma concludes $225m Mitobridge acquisition

Japanese company Astellas Pharma has concluded the acquisition of 100% equity in US-based biotechnology firm Mitobridge for a total of...Read More... The post Astellas Pharma concludes $225m Mitobridg...

Astellas exec to join Alkermes

The head of Japanese pharma major Astellas’ (TYO: 4503) US operations is moving to take up a top position…

BRIEF—Astellas appoints Kenji Yasukawa as president and CEO

Japanese drug major Astellas Pharma (TYO: 4503) has announced that its board of directors approved a…

Astellas upgrades Universal Cells licensing deal to a buy

Japanese pharma major Astellas is to pay up to $102.5 million in upfront and milestone payments to acquire…

Astellas Pharma acquires Universal Cells for $102m

Astellas Pharma has acquired Universal Cells for $102.5m in a move to utilize the latter’s technology to produce pluripotent stem cells that have the potential to lower immunological rejection in va...

BRIEF—Astellas to pursue Asian filings for novel second-line RA therapy

Japan’s Astellas Pharma says two Phase III trials - RAJ3 and RAJ4 - of ASP015K (peficitinib hydrobromide)…

Astellas wins expanded label to include pediatric use for oral solifenacin

Tokyo-based Astellas Pharma has been awarded EU approval for its neurogenic detrusor overactivity (NDO)…

Drugs and Medications [277 Associated Drugs and Medications listed on BioPortfolio]

Vesicare [Astellas Pharma Technologies, Inc.]

These highlights do not include all the information needed to use VESIcare safely and effectively. See full prescribing information for VESIcare. VESIcare (solifenacin succinate) tablets Initial U.S. ...

Alcohol prep pad [Büttner-Frank GmbH]

La prairie switzerland [Juvena Produits de Beaute GMBH]

Package.Label Principle Display Panel

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

PubMed Articles [33 Associated PubMed Articles listed on BioPortfolio]

Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder.

Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transu...

Moving pharma contracting into the era of accountability.

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

Ocular Impression-Taking-Which Material Is Best?

To assess the efficacy and effect on clinical signs of a polyvinylsiloxane (Tresident; Shütz Dental Group GmbH, Germany) compared with an irreversible hydrocolloid (Orthoprint; Zhermack SpA, Badia Po...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

The purpose of the study is to provide access to continued treatment for subjects who participated in other Astellas sponsored ASP2215 trials and for whom the Investigator feels the subjec...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Companies [1255 Associated Companies listed on BioPortfolio]

Astellas Pharma Canada, Inc.

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the he...

Astellas Pharma Global Development

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of peo...

Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals...

Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around...

Potenza Therapeutics, Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and rel...

More Information about "Astellas Pharma GmbH" on BioPortfolio

We have published hundreds of Astellas Pharma GmbH news stories on BioPortfolio along with dozens of Astellas Pharma GmbH Clinical Trials and PubMed Articles about Astellas Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Astellas Pharma GmbH Companies in our database. You can also find out about relevant Astellas Pharma GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record